Last edition
News about "AL Amyloidosis"
CARES Phase 3 Trial Highlights Anselamimab Potential in Kappa Light Chain Amyloidosis
Anselamimab demonstrated promising efficacy in the phase 3 CARES programme, showing a 62 percent improvement in survival and a 71 percent reduction in cardiovascular hospitalisations among patients with kappa light-chain amyloidosis, despite the study not meeting its primary endpoint in the overall light-chain amyloidosis population.
AL Amyloidosis | 01/06/2026 | By News Bureau
Immix Biopharma Gets US FDA Breakthrough Therapy Designation for NXC-201
Immix Biopharma has received US FDA Breakthrough Therapy Designation for its CAR-T candidate NXC-201, based on positive interim phase-II results from the NEXICART-2 study presented at the ASH 2025 annual meeting, with final data expected later this year followed by a planned Biologics Licence Application (BLA) submission.
AL Amyloidosis | 29/01/2026 | By News Bureau | 160
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy